Lyell Immunopharma, Inc. expected to post a loss of $2.14 a share - Earnings Preview
Lyell Immunopharma, Inc. LYEL.O is expected to show a fall in quarterly revenue when it reports results for the period ending December 31 2026
The South San Francisco California-based company is expected to report a 79.2% decrease in revenue to $1.25 thousand from $6 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lyell Immunopharma, Inc. is for a loss of $2.14 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.1% in the last three months.
Wall Street's median 12-month price target for Lyell Immunopharma, Inc. is $41.50, about 176.7% above its last closing price of $15.00
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2026 | -2.08 | -2.07 | -1.86 | Beat | 10.3 |
Jun. 30 2026 | -2.03 | -2.02 | -1.92 | Beat | 4.8 |
Mar. 31 2026 | -2.35 | -2.36 | -1.10 | Beat | 53.5 |
Dec. 31 2025 | -1.89 | -2.23 | -7.50 | Missed | -236.1 |
Sep. 30 2025 | -2.66 | -2.64 | -2.13 | Beat | 19.4 |
Jun. 30 2025 | -3.52 | -3.58 | -2.89 | Beat | 19.3 |
Mar. 31 2025 | -3.53 | -3.60 | -3.54 | Beat | 1.7 |
Dec. 31 2024 | -2.63 | -3.40 | -4.00 | Missed | -17.6 |
This summary was machine generated November 6 at 22:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)